Roth Mkm Reiterates “Buy” Rating for LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “buy” rating reissued by equities researchers at Roth Mkm in a research report issued on Thursday,Benzinga reports. They presently have a $117.00 price target on the medical instruments supplier’s stock, up from their prior price target of $108.00. Roth Mkm’s target price points to a potential upside of 6.71% from the company’s previous close.

Several other brokerages have also commented on LMAT. Citizens Jmp boosted their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a research note on Thursday. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Finally, Barrington Research reaffirmed an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research note on Friday, February 20th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, LeMaitre Vascular currently has an average rating of “Hold” and a consensus target price of $104.83.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT traded up $18.26 during trading on Thursday, hitting $109.64. 452,789 shares of the company were exchanged, compared to its average volume of 153,110. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $112.65. The company has a market cap of $2.49 billion, a price-to-earnings ratio of 47.11, a PEG ratio of 2.01 and a beta of 0.72. The firm’s fifty day moving average price is $85.98 and its 200 day moving average price is $88.12.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The firm had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same quarter last year, the business earned $0.49 earnings per share. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Institutional Trading of LeMaitre Vascular

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in LeMaitre Vascular by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after purchasing an additional 21,946 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of LeMaitre Vascular by 13.4% during the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after purchasing an additional 111,193 shares during the last quarter. Geneva Capital Management LLC boosted its stake in shares of LeMaitre Vascular by 6.0% during the 2nd quarter. Geneva Capital Management LLC now owns 915,238 shares of the medical instruments supplier’s stock worth $76,010,000 after purchasing an additional 51,489 shares during the last quarter. State Street Corp grew its holdings in shares of LeMaitre Vascular by 0.8% during the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after buying an additional 6,130 shares in the last quarter. Finally, Congress Asset Management Co. raised its position in shares of LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat expectations: LMAT reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M vs. $62.98M, with revenue up 15.7% YoY and healthy margins — direct evidence of underlying business momentum. Earnings Release & Conference Call
• Positive Sentiment: Management raised guidance: Q1 EPS guidance of $0.640–0.690 (above consensus) and FY2026 EPS guidance of $2.810–3.010 (well above the $2.61 consensus) plus higher revenue targets — this upgrades the company’s near- and full-year outlook. Guidance Press Release
• Positive Sentiment: Dividend increased: LMAT raised its quarterly dividend 25% to $0.25 (annualized yield ~1.1%), signaling confidence in cash flow and returning capital to shareholders — often viewed favorably by income-focused investors.
• Positive Sentiment: Analyst price-target upgrade: Citizens Jmp raised its price target to $118 and kept a “market outperform” rating, providing third‑party validation that could attract additional buying interest. Price Target Raise Coverage
• Neutral Sentiment: Earnings call transcript now available for deeper detail on drivers (product demand, margin drivers, and regional trends) — useful for investors wanting to validate management’s commentary. Earnings Call Transcript
• Neutral Sentiment: Industry/expectations coverage: Recent analysis pieces summarize the beat and guidance changes; these help frame market expectations but don’t add new company-specific data. Exploring Earnings Expectations

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.